Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy.

J Clin Oncol · 2022 · PMC9061145 · PMID 35077204

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significanceP = .06so close (0.05 < p ≤ 0.1)

The differences in risk for coexistence of diagnoses between patients and comparators did not reach statistical significance, although second cancer plus DCS and DCS plus DRS were borderline ( P = .06 for both).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.